Prioritization of Molecular Targets for Antimalarial Drug Discovery
Author(s)
Forte, Barbara; Ottilie, Sabine; Plater, Andrew; Campo, Brice; Dechering, Koen J; Gamo, Francisco Javier; Goldberg, Daniel E; Istvan, Eva S; Lee, Marcus; Lukens, Amanda K; McNamara, Case W; Niles, Jacquin C; Okombo, John; Pasaje, Charisse Flerida A; Siegel, Miles G; Wirth, Dyann; Wyllie, Susan; Fidock, David A; Baragaña, Beatriz; Winzeler, Elizabeth A; Gilbert, Ian H; ... Show more Show less
DownloadPublished version (2.627Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MalDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.
Date issued
2021Department
Massachusetts Institute of Technology. Department of Biological EngineeringJournal
ACS Infectious Diseases
Publisher
American Chemical Society (ACS)
Citation
Forte, Barbara, Ottilie, Sabine, Plater, Andrew, Campo, Brice, Dechering, Koen J et al. 2021. "Prioritization of Molecular Targets for Antimalarial Drug Discovery." ACS Infectious Diseases, 7 (10).
Version: Final published version